Novel integrative genomic tool for interrogating lithium response in bipolar disorder

Translational Psychiatry

Volumn 5, Issue 2, 2015, Pages

  Hunsberger, J G ^a   Chibane, F L ^a   Elkahloun, A G ^b   Henderson, R ^c   Singh, R ^d   Lawson, J ^e   Cruceanu, C ^f,g   Nagarajan, V ^c   Turecki, G ^f   Squassina, A ^h   Medeiros, C D ^f   Del Zompo, M ^h   Rouleau, G A ^g   Alda, M ⁱ   Chuang, D M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d LOCKHEED MARTIN   (United States)

^e KG Science Assoc LLC   (United States)

^f MCGILL UNIVERSITY   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h UNIVERSITY OF CAGLIARI   (Italy)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHASE PROMOTING COMPLEX SUBUNIT 3; LARS PROTEIN; LITHIUM; MESSENGER RNA; MICRORNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PROTEIN; THRAP3 PROTEIN; TRP PROTEIN; UNCLASSIFIED DRUG; LITHIUM DERIVATIVE; TRANQUILIZER;

BIPOLAR DISORDER; CELL SURVIVAL; CLINICAL ASSESSMENT TOOL; DOWN REGULATION; GENE EXPRESSION PROFILING; GENOMICS; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; LONG TERM CARE; LYMPHOBLASTOID CELL; NERVE DEGENERATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT RESPONSE; ADULT; DEVICES; FEMALE; GENETICS; MALE; MIDDLE AGED; PHARMACOGENETICS; PROCEDURES; STATISTICS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; FEMALE; GENOMICS; HUMANS; LITHIUM COMPOUNDS; MALE; MICRORNAS; MIDDLE AGED; PHARMACOGENETICS; STATISTICS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927770254     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.139     Document Type: Review

References (34)

1. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50: 143-151.
2. Goodwin F, Jamison K. Manic-Depressive Illness. Oxford University Press: Oxford, UK, 2007.
3. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552.
4. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68: 241-251.
5. Garnham J, Munro A, Slaney C, Macdougall M, Passmore M, Duffy A et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord. 2007; 104: 185-190.
6. Baldessarini RJ, Tondo L. Does lithium treatment still work Evidence of stable responses over three decades. Arch Gen Psychiatry 2000; 57: 187-190.
7. Coryell W. Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. Bipolar Disord. 2009; 11: 77-83.
8. Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium. Mol Interv 2004; 4: 259-272.
9. Severino G, Squassina A, Costa M, Pisanu C, Calza S, Alda M et al. Pharmacogenomics of bipolar disorder. Pharmacogenomics 2013; 14: 655-674.
10. Alda M, Grof P, Rouleau GA, Turecki G, Young LT. Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1038-1045.
11. Turecki G, Grof P, Grof E, D'Souza V, Lebuis L, Marineau C et al. Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry 2001; 6: 570-578.
12. Alda M, Keller D, Grof E, Turecki G, Cavazzoni P, Duffy A et al. Is lithium response related to G(s)alpha levels in transformed lymphoblasts from subjects with bipolar disorder J Affect Disord 2001; 65: 117-122.
13. Sun X, Young LT, Wang JF, Grof P, Turecki G, Rouleau GA et al. Identification of lithium-regulated genes in cultured lymphoblasts of lithium responsive subjects with bipolar disorder. Neuropsychopharmacology 2004; 29: 799-804.
14. Sugawara H, Iwamoto K, Bundo M, Ishiwata M, Ueda J, Kakiuchi C et al. Effect of mood stabilizers on gene expression in lymphoblastoid cells. J Neural Transm 2010; 117: 155-164.
15. Asai T, Bundo M, Sugawara H, Sunaga F, Ueda J, Tanaka G et al. Effect of mood stabilizers on DNA methylation in human neuroblastoma cells. Int J Neuropsychopharmacology 2013; 16: 2285-2294.
16. Cruceanu C, Alda M, Grof P, Rouleau GA, Turecki G. Synapsin II is involved in the molecular pathway of lithium treatment in bipolar disorder. PloS One 2012; 7: e32680.
17. Glatt SJ, Chandler SD, Bousman CA, Chana G, Lucero GR, Tatro E et al. Alternatively spliced genes as biomarkers for schizophrenia, bipolar disorder and psychosis: a blood-based spliceome-profiling exploratory study. Curr Pharmacogenomics Person Med 2009; 7: 164-188.
18. Greiner HM, Horn PS, Holland K, Collins J, Hershey AD, Glauser TA. mRNA blood expression patterns in new-onset idiopathic pediatric epilepsy. Epilepsia 2013; 54: 272-279.
19. Han G, Wang J, Zeng F, Feng X, Yu J, Cao HY et al. Characteristic transformation of blood transcriptome in Alzheimer's disease. J Alzheimers Dis 2013; 35: 373-386.
20. Sabatino G, Rigante L, Minella D, Novelli G, Della Pepa GM, Esposito G et al. Transcriptional profile characterization for the identification of peripheral blood biomarkers in patients with cerebral aneurysms. J Biol Regul Homeost Agents 2013; 27: 729-738.
21. Fruchterman TMJ, Reingold EM. Graph drawing by force-directed placement. Softw Pract Exp 1991; 21: 1129-1164.
22. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 2010; 15: 1176-1189.
23. Song YJ, Tian XB, Zhang S, Zhang YX, Li X, Li D et al. Temporal lobe epilepsy induces differential expression of hippocampal miRNAs including let-7e and miR-23a/b. Brain Res 2011; 1387: 134-140.
24. Zucchi FC, Yao Y, Ward ID, Ilnytskyy Y, Olson DM, Benzies K et al. Maternal stress induces epigenetic signatures of psychiatric and neurological diseases in the offspring. PloS One 2013; 8: e56967.
25. Lehmann SM, Kruger C, Park B, Derkow K, Rosenberger K, Baumgart J et al. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci 2012; 15: 827-835.
26. Qin B, Xiao B, Liang D, Li Y, Jiang T, Yang H. MicroRNA let-7c inhibits Bcl-xl expression and regulates ox-LDL-induced endothelial apoptosis. BMB Rep 2012; 45: 464-469.
27. Corbin R, Olsson-Carter K, Slack F. The role of microRNAs in synaptic development and function. BMB Rep 2009; 42: 131-135.
28. Davis CJ, Bohnet SG, Meyerson JM, Krueger JM. Sleep loss changes microRNA levels in the brain: a possible mechanism for state-dependent translational regulation. Neurosci Lett 2007; 422: 68-73.
29. Cai WY, Wei TZ, Luo QC, Wu QW, Liu QF, Yang M et al. The Wnt-beta-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. J Cell Sci 2013; 126: 2877-2889.
30. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by 'walking' the genes of three genomes. J Biomed Inform 2011; 44: 839-847.
31. Morgan-Smith M, Wu Y, Zhu X, Pringle J, Snider WD. GSK-3 signaling in developing cortical neurons is essential for radial migration and dendritic orientation. Elife 2014; 3: e02663.
32. Kim WY, Wang X, Wu Y, Doble BW, Patel S, Woodgett JR et al. GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci 2009; 12: 1390-1397.
33. Oruch R, Elderbi MA, Khattab HA, Pryme IF, Lund A. Lithium: a review of pharmacology, clinical uses, and toxicity. Eur J Pharmacol 2014; 740C: 464-473.
34. Carter L, Zolezzi M, Lewczyk A. An updated review of the optimal lithium dosage regimen for renal protection. Can J Psychiatry 2013; 58: 595-600.